Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial (Lancet, 2020)

(untitled) - Ramasamy, MN; Minassian, AM; Ewer, KJ; Flaxman, AL; Folegatti, PM; Owens, DR; Voysey, M; Aley, PK; Angus, B; Babbage, G; Belij-Rammerstorfer, S; Berry, L; et al.